ArticleFrontiers in nutrition2024
The preoperative hemoglobin, albumin, lymphocyte, and platelet score (HALP) as a prognostic indicator in patients with non-small cell lung cancer.
Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Predictive value of HALP score for clinical outcomes in lung cancer patients: a systematic review and meta-analysis.Translational cancer research · 2026Article
- Prognostic Significance of the CALM Index in Surgically Resected Non-Small Cell Lung Cancer.Journal of clinical medicine · 2026Article
- Prognostic role of hemoglobin, albumin, lymphocyte and platelet score in esophageal cancer: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Machine learning-based prognostic model integrating preoperative HALP score and lactate dehydrogenase for predicting postoperative recurrence of prostate cancer.World journal of surgical oncology · 2026Article
- HALP outperforms systemic inflammatory biomarkers for prognosis in locally advanced cervical cancer treated with concurrent chemoradiotherapy.Biomolecules & biomedicine · 2026Article
- Prognostic Value of HALP and PNI Scores in Predicting 6-Month Mortality Among Geriatric Hip Fracture Patients.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Application and Modification of Nutritional Assessment Tools in Hematologic Malignancies.Cancers · 2026Article
- Mean Corpuscular Volume as a Prognostic Marker in Patients with Non-Small Cell Lung Cancer Undergoing Surgical Resection: A Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- HALP score outperforms systemic inflammatory biomarkers for prognosis in locally advanced rectal cancer.Biomolecules & biomedicine · 2026Observational
- Correlation between novel hematological parameters and assisted pregnancy outcome in frozen-thawed embryo transfer patients.Frontiers in cell and developmental biology · 2026Article
- Low prognostic nutritional index score is associated with lymph node metastasis in patients with breast cancer, whereas hemoglobin-albumin-lymphocyte-platelet score is not.Frontiers in oncology · 2026Article
- Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI.Biomarkers in medicine · 2025Article
- The Prognostic Value of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Lung Cancer: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Preoperative plasma fibrinogen combined with the platelet-to-lymphocyte ratio (F-PLR) serves as a prognostic indicator in patients with non-small cell lung cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Hemoglobin, Albumin, Lymphocyte, and Platelet score (HALP) is an inflammatory nutrition-related biomarker based on hemoglobin and albumin levels, as well as the lymphocyte and platelet load index, which has been reported to be associated with the prognosis of various types of tumors. This study aims to investigate the prognostic value of HALP in patients with non-small cell lung cancer (NSCLC). Methods: A total of 2,428 patients with NSCLC were enrolled in the INSCOC study. Time-patient survival trends were validated using Kaplan-Meier curves and log-rank tests. The Restricted Cubic Spline function was used to analyze the relationship between the HALP index and overall survival (OS). The Cox regression model was used for univariate and multivariate analyses. Results: The study included 2,053 patients with detailed biological information and follow-up data, consisting of 1,346 men (65.6%) and 707 women (34.4%). Within this cohort, 138 patients (6.7%) had stage I disease, 282 (13.7%) had stage II, 477 (23.2%) had stage III, and 1,156 (56.3%) had stage IV. A total of 536 patients (26.1%) underwent surgery, 1,494 (72.8%) received chemotherapy, and 271 (13.2%) received radiotherapy. The 1-, 2-, 3-, and 5-year survival rates for patients with NSCLC were 68.6, 48.6, 37.4, and 30.9%, respectively. The optimal cut-off for HALP was determined to be 29.71, with a sensitivity of 53.1% and specificity of 62.9%, leading to the categorization of patients into low (<29.71) ( Conclusion: The HALP index can be used as an independent prognostic factor for patients with NSCLC, offering clinicians a reference to identify high-risk patient with poor long-term prognoses and improve individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.